Canton Strategic Holdings Inc CNTN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Canton Strategic Holdings, Inc. Delivers Third Quarter Canton Network Ecosystem Update
-
Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results
-
Three New Directors Elected to the Board of Canton Strategic Holdings, Inc.
-
Canton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC
-
Tharimmune Shares Drop Premarket Following FDA Feedback on Plan for Lead Clinical Asset
-
Tharimmune Shares Rise After $540 Million Private Placement
Trading Information
- Previous Close Price
- $1.87
- Day Range
- $1.66–1.88
- 52-Week Range
- $1.66–6.89
- Bid/Ask
- $1.73 / $1.75
- Shares Outstanding
- 79.68M
- Market Cap
- $135.06M
- Volume/Avg
- 1M / 778,845
Key Statistics
- Price/Earnings (Normalized)
- 2.85
- Price/Sales
- 155.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 12
- Website
- https://www.cantonstrategic.com
Valuation
|
Metric
|
CNTN
|
|---|---|
Price/Earnings (Normalized) | 2.85 |
Price/Book Value | 0.29 |
Price/Sales | 155.06 |
Price/Cash Flow | — |
Price/Earnings
CNTN
Financial Strength
|
Metric
|
CNTN
|
|---|---|
Quick Ratio | 14.18 |
Current Ratio | 15.70 |
Interest Coverage | −8,232.42 |
Quick Ratio
CNTN
Profitability
|
Metric
|
CNTN
|
|---|---|
Return on Assets (Normalized) | 0.11% |
Return on Equity (Normalized) | 0.14% |
Return on Invested Capital (Normalized) | −0.10% |
Return on Assets
CNTN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|qx@CJ&^ | LOCK|tn^V | $127B | |||
| Moderna Inc
MRNA
| LOCK|$kK%m<Y | LOCK|V?? | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#y<jLN | LOCK|w$WRg | $81B | |||
| argenx SE ADR
ARGX
| LOCK|zP!dH^ | LOCK|dD | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#YZRCg | LOCK|Zrq | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$!r?B<& | LOCK|?zw^& | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|q<sm>rQ | LOCK|#<@#% | $27B | |||
| Incyte Corp
INCY
| LOCK|DJ^&&x | LOCK|xF | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|CJJ!cHQ | LOCK|FV | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|YkFm$$$ | LOCK|j$w | $14B |
United States